J. R. Mel

Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Miguel Martín, Álvaro Rodríguez-Lescure, A. Ruiz et al. · JNCI Journal of the National Cancer Institute · 2008 · 239 citations · Full text

Medicine, Oncology, Pharmacology +15

Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer

Miguel Martín, Miguel Ángel Seguí, Antonio Antón et al. · New England Journal of Medicine · 2010 · 208 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

Miguel Martín, Aňa Lluch, Miguel Ángel Seguí et al. · Annals of Oncology · 2006 · 204 citations · Full text

Medicine, Oncology, Pharmacology +17

Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

Miguel Martín, Monserrat Muñoz, A. Balil et al. · The Lancet Oncology · 2007 · 186 citations

Medicine, Oncology, Pharmacology +16

Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer

Jaime Feliú, C. Castañón, Antonieta Salud et al. · British Journal of Cancer · 2005 · 36 citations · Full text

Medicine, Oncology, Pharmacology +14